Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis

Company Overview

Syros Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, that is pioneering a new class of targeted therapeutics by focusing on the control of gene expression. Founded in 2015 as a spin-out from the Broad Institute, Syros leverages its proprietary gene control platform to identify and drug key noncoding regions of the genome that regulate disease-driving genes. The company’s approach aims to convert previously undruggable gene targets into precise medicines for patients with cancer and rare genetic disorders.

Syros’ lead development candidate, tamibarotene (SY-1425), is an oral, selective RARα agonist being evaluated in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) characterized by RARA dependence. In addition, Syros is advancing SY-1365, a selective CDK7 inhibitor, through early-stage studies in solid tumors and hematologic malignancies. Beyond oncology, the company has preclinical programs in rare genetic diseases, including SY-2101, an investigational therapy for Gaucher disease.

Utilizing a research site in Cambridge and collaborations with academic and industry partners, Syros aims to accelerate its pipeline by integrating genomics, chemical biology and translational science. The company emphasizes a disciplined clinical strategy, selecting patient populations based on molecular biomarkers to maximize the potential for clinical benefit. Syros Pharmaceuticals is publicly traded on the NASDAQ under the symbol SYRS and continues to build a diversified portfolio of gene control–based medicines.

Key Stats

• Today's Range: $0.0011 to $0.0021
• 50-Day Range: $0.00 to $0.03
• 52-Week Range: $0.00 to $0.10
• Volume: 16,567 shs
• Average Volume: 164,099 shs
• Market Capitalization: $29.52 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.00
• Consensus Rating: Hold

Syros Pharmaceuticals Stock Analysis - MarketRank™

Syros Pharmaceuticals scored higher than 86% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Syros Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

Syros Pharmaceuticals has a consensus price target of $1.00, representing about 90,809.1% upside from its current price of $0.00.

Amount of Analyst Coverage

Syros Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Syros Pharmaceuticals are expected to decrease in the coming year, from ($2.94) to ($2.97) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Syros Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Syros Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Syros Pharmaceuticals has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.19% of the float of Syros Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Syros Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Syros Pharmaceuticals has recently decreased by 35.64%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Syros Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Syros Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -0.88

Percentage of Shares Shorted

0.19% of the float of Syros Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Syros Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Syros Pharmaceuticals has recently decreased by 35.64%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Syros Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Syros Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for SYRS on MarketBeat in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Syros Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.26% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.47% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SYRS Stock Analysis - Frequently Asked Questions

How have SYRS shares performed this year?

Syros Pharmaceuticals' stock was trading at $0.2298 at the beginning of 2025. Since then, SYRS stock has decreased by 99.5% and is now trading at $0.0011.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) released its quarterly earnings results on Thursday, October, 31st. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.08.
Read the conference call transcript.

When did Syros Pharmaceuticals' stock split?

Shares of Syros Pharmaceuticals reverse split on the morning of Monday, September 19th 2022.The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Syros Pharmaceuticals IPO?

Syros Pharmaceuticals (SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' top institutional shareholders include FNY Investment Advisers LLC. Insiders that own company stock include Jason Haas, Conley Chee, Timothy Tyson, David Roth, Richard A Young, Eric R Olson and Nancy A Simonian.
View institutional ownership trends.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Syros Pharmaceuticals investors own include Salesforce (CRM), QUALCOMM (QCOM), Bank of America (BAC), Bristol Myers Squibb (BMY), Pfizer (PFE), Twilio (TWLO) and AbbVie (ABBV).

Company Calendar

• Last Earnings: 10/31/2024
• Today: 9/15/2025
• Next Earnings (Estimated): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SYRS
• CIK: 1556263
• Web: www.syros.com
• Phone: (617) 744-1340
• Fax: N/A
• Employees: 120
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Syros Pharmaceuticals: $1.00
• High Price Target: $1.00
• Low Price Target: $1.00
• Potential Upside/Downside: +90,809.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$164.57 million
• Net Margins: N/A
• Pretax Margin: -25,275.20%
• Return on Equity: -3,369.56%
• Return on Assets: -97.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.25
• Quick Ratio: 2.25

Sales & Book Value

• Annual Sales: $386 thousand
• Price / Sales: 0.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.79 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 26,832,000
• Free Float: 23,542,000
• Market Cap: $29.52 thousand
• Optionable: Optionable
• Beta: 1.31